Showing results (1091-1100 of 6,501) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|November 8, 2014
Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigenYuhua Li, Weijun Zhou, Jingwen Du, et al.Cancer Immunology, Immunotherapy : CII|October 16, 2014
Armed antibodies for cancer treatment: a promising tool in a changing eraRiccardo Danielli, Roberto Patuzzo, Pier Adelchi Ruffini, et al.Cancer Immunology, Immunotherapy : CII|September 20, 2014
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?Luana Calabrò, Giovanni Luca Ceresoli, Alessandra di Pietro, et al.Cancer Immunology, Immunotherapy : CII|November 5, 2020
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institutionR Kleef, R Nagy, A Baierl, et al.Cancer Immunology, Immunotherapy : CII|November 12, 2020
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreementPhillip M Kemp Bohan, Robert C Chick, Annelies T Hickerson, et al.Cancer Immunology, Immunotherapy : CII|September 4, 2020
Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodiesAlexandra Frelau, Xavier Palard-Novello, Eva Jali, et al.Cancer Immunology, Immunotherapy : CII|November 2, 2020
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parametersLata Singh, Mithalesh Kumar Singh, Maria Cristina Kenney, et al.Cancer Immunology, Immunotherapy : CII|November 3, 2020
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patientElena Anghileri, Natalia Di Ianni, Rosina Paterra, et al.Cancer Immunology, Immunotherapy : CII|November 3, 2020
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomesMaryam Moradi-Chaleshtori, Mojgan Bandehpour, Sara Soudi, et al.Cancer Immunology, Immunotherapy : CII|February 15, 2020
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemiaDenise Risnik, Ana Colado, Enrique Podaza, et al.Pageof 651